跳到主要內容

臺灣博碩士論文加值系統

(216.73.216.191) 您好!臺灣時間:2026/11/19 18:21
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:陳立亭
研究生(外文):CHEN,LI-TING
論文名稱:探討Blimp-1基因轉殖於T細胞對神經膠質瘤免疫監控之影響
論文名稱(外文):To Investigate the Effect of T cell Specific Transgenic Blimp-1 Expression on Immune Surveillance of Glioma-Bearing Mice
指導教授:洪東源洪東源引用關係
指導教授(外文):HONG,DONG-YUAN
口試委員:林明宏、陳瀅
口試委員(外文):LIN,MING-HONG、CHEN,YING
口試日期:2016-05-09
學位類別:碩士
校院名稱:國防醫學院
系所名稱:微生物及免疫學研究所
學門:生命科學學門
學類:微生物學類
論文種類:學術論文
論文出版年:2016
畢業學年度:104
語文別:中文
論文頁數:48
中文關鍵詞:神經膠質瘤
外文關鍵詞:Glioma、Blimp-1
相關次數:
  • 被引用被引用:0
  • 點閱點閱:209
  • 評分評分:
  • 下載下載:4
  • 收藏至我的研究室書目清單書目收藏:0
多型性神經膠母細胞瘤(Glioblastoma multiforme;GBM)為腦瘤的一種,是屬於中樞神經系統中最常見的原發性惡性腫瘤。其標準治療方式為手術切除並給予口服化學藥物治療以及輔助性放射線治療。根據研究多型性神經膠母細胞瘤對於化學藥物以及放射線治療皆具有抗性,加上它具有高度侵襲性以及快速生長的特性,導致手術無法完整切除進而容易復發,為造成死亡率高居不下之原因。基於上述原因,目前對於多型性神經膠母細胞瘤的研究主要關注在基因治療以及免疫治療。
根據研究顯示,多型性神經膠母細胞瘤主要是藉由抑制第一型輔助型T細胞(Type I T helper cell;Th1)以及增加調節性T細胞(Regulatory T cell;Treg)來造成免疫抑制。
B淋巴球誘導成熟蛋白(B lymphocyte-induced maturation protein-1;Blimp-1),根據先前研究表示,Blimp-1對於T細胞的發展相當重要,特別的是它會增加調節性T細胞(Treg)的功能,並同時抑制第一型輔助性T細胞(Th1),以及抑制第十七型輔助性T細胞(Th17)的分化。
本篇研究利用Blimp-1在T細胞專一性基因轉殖小鼠,利用原位注射腦瘤的方式,去探討當Blimp-1過度表現在T細胞上,對於腦瘤的生長是否有影響。研究結果顯示,Blimp-1 在T細胞專一性基因轉殖小鼠的組別與控制組相比,可以看到多型性神經膠母細胞瘤的病程進展的較快速,體重下降程度也較大;細胞分析則可以看到基因轉殖組的T細胞明顯下降,但調節性T細胞卻增加,因此可以推測Blimp-1對於免疫細胞清除多型性神經膠母細胞瘤有相當大的影響力。

Glioblastoma multiforme (GBM) is kind of glioma, it’s also the most common primary central nervous system malignant tumor. Standard treatment includes surgical resection, chemo-therapy combine radiation therapy. However, previous research indicated that GBM grow fast and is highly invasive. Despite standard treatment, the median survival of GBM patients is less than 16 months. For these reasons, the present study focuses on gene therapy and immunotherapy for GBM.
Immune system plays an important role on eliminating abnormal cells (e.g., over-proliferated cells). However, the immune cells are deregulated in GBM. Previous researches have indicated that GBM leads to immune suppression by downregulation of Type I T helper cells and upregulation of Treg cells. B lymphocyte-induced maturation protein-1 (Blimp-1), which is important for T cell maturation, can enhance Treg cells function, suppress Th1 cells and impede Th17 cells.
In our study, we established orthotropic syngeneic brain tumor model on T cell specific Blimp-1 transgenic mice to investigate the effect of T cell specific transgenic Blimp-1 expression on immune surveillance of glioma-bearing mice. The results show that the tumor growth rate was faster in Blimp-1 transgenic mice compared with wild type mice. T cell population is decreased, and the Treg cell population is increased in brain of glioma-bearing Blimp-1 transgenic mice. These results suggest Blimp-1 is important for immune surveillance in glioma.

目錄 .................................................................... I
表目錄 ................................................................ III
圖目錄 ................................................................. IV
中文摘要 ............................................................... VI
Abstract ............................................................. VIII
第一章 序論 ............................................................. 1
第一節 神經膠質瘤 (Glioma) ........................................... 1
壹、 神經膠質瘤之介紹 .............................................. 1
貳、 神經膠質瘤之治療 .............................................. 1
參、 神經膠質瘤造成之免疫抑制反應 ................................... 2
第二節 B淋巴細胞成熟誘發蛋白1 (Blimp-1) .............................. 3
壹、 B淋巴細胞成熟誘發蛋白1 (Blimp-1)之介紹 .......................... 3
貳、 B淋巴細胞成熟誘發蛋白1 (Blimp-1)與免疫細胞之關聯性 .............. 4
第三節 免疫系統 ...................................................... 5
壹、 免疫系統之介紹 ................................................ 5
貳、 免疫系統與腦瘤的免疫反應 ....................................... 6
第四節 研究目的與動機 ................................................ 7
第二章 材料與方法 ....................................................... 8
第一節:實驗材料 ....................................................... 8
壹、 細胞 .......................................................... 8
貳、 Lentivirus質體 (plasmids)構築 ................................. 8
參、 實驗動物 ...................................................... 8
第二節: 實驗方法 ...................................................... 9
壹、 細胞培養 ...................................................... 9
II
貳、 Lentivirus質體 (plasmids)構築生產及感染細胞 .................. 10
參、 動物實驗 ..................................................... 12
第三章 結果 ............................................................ 18
第一節 建構原位生長腦瘤在Blimp-1基因轉殖小鼠與野生型小鼠 ............. 18
第二節 探討Blimp-1在T細胞特異性轉殖是否會對腦瘤生長造成影響 ......... 19
第三節 分析腦瘤小鼠的頸部淋巴結淋巴細胞與中樞神經浸潤淋巴細胞 ......... 20
第四節 分析組織切片探討腫瘤大小 ....................................... 24
第四章 討論 ............................................................ 25
第五章 結論 ............................................................ 28
第六章 參考資料 ........................................................ 29
圖表 ................................................................... 31
附圖 ................................................................... 46
1.Kleihues, P., P.C. Burger, and B.W. Scheithauer, The new WHO classification of brain tumours. Brain Pathol, 1993. 3(3): p. 255-68.
2.Rao, J.S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 2003. 3(7): p. 489-501.
3.Maher, E.A., et al., Malignant glioma: genetics and biology of a grave matter. Genes Dev, 2001. 15(11): p. 1311-33.
4.Louis, D.N., Molecular pathology of malignant gliomas. Annu Rev Pathol, 2006. 1: p. 97-117.
5.Omuro, A. and L.M. DeAngelis, Glioblastoma and other malignant gliomas: a clinical review. Jama, 2013. 310(17): p. 1842-50.
6.Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96.
7.Heimberger, A.B. and J.H. Sampson, Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol, 2011. 13(1): p. 3-13.
8.Gabrilovich, D., et al., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998. 92(11): p. 4150-66.
9.Platten, M., W. Wick, and M. Weller, Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech, 2001. 52(4): p. 401-10.
10.Ge, L., et al., Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol, 2010. 2010: p. 296453.
11.Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996. 2(10): p. 1096-103.
12.Munn, D.H. and A.L. Mellor, IDO and tolerance to tumors. Trends Mol Med, 2004. 10(1): p. 15-8.
13.Keller, A.D. and T. Maniatis, Identification and characterization of a novel repressor of beta-interferon gene expression. Genes Dev, 1991. 5(5): p. 868-79.
14.Turner, C.A., Jr., D.H. Mack, and M.M. Davis, Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell, 1994. 77(2): p. 297-306.
15.Vincent, S.D., et al., The zinc finger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for specification of primordial germ cells in the mouse. Development, 2005. 132(6): p. 1315-25.
16.Turner, C.A., Jr., D.H. Mack, and M.M. Davis, Pillars article: Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. 1994. J Immunol, 2010. 185(1): p. 5-14.
17.Fink, P.J., T cells join the Blimp-1 brigade. Nat Immunol, 2006. 7(5): p. 445-6.
18.Kallies, A. and S.L. Nutt, Terminal differentiation of lymphocytes depends on Blimp-1. Curr Opin Immunol, 2007. 19(2): p. 156-62.
19.Martins, G. and K. Calame, Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol, 2008. 26: p. 133-69.
20.Martins, G.A., et al., Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med, 2008. 205(9): p. 1959-65.
21.Cimmino, L., et al., Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene expression. J Immunol, 2008. 181(4): p. 2338-47.
22.Cretney, E., et al., The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol, 2011. 12(4): p. 304-11.
23.Litman, G.W., J.P. Cannon, and L.J. Dishaw, Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol, 2005. 5(11): p. 866-79.
24.Pancer, Z. and M.D. Cooper, The evolution of adaptive immunity. Annu Rev Immunol, 2006. 24: p. 497-518.
25.Schaefer, L.K., D.G. Menter, and T.S. Schaefer, Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell Signal, 2000. 12(3): p. 143-51.
26.Humphries, W., et al., The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am, 2010. 21(1): p. 125-37.
27.Izumoto, S., et al., Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg, 2008. 108(5): p. 963-71.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top